GlassScriptPhysician profile
Kendra D Proctor
NPI 1396764981
$7,738.57
in general payments reported to CMS, 2019-2025
34 companies · $1,494 in 2025
The $1,494 reported for 2025 was more than what 90% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,351 · 2022: $1,440 · 2023: $1,654 · 2024: $1,799 · 2025: $1,494.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,854 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,853.84 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,342.72 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $1,170.39 | 2021-2025 | |
| Glaxosmithkline, LLC. | $1,022.84 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $816.35 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $571.62 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $393.40 | 2021-2025 | |
| Exact Sciences Corporation | $247.74 | 2023-2025 | Cologuard Collection Kit |
| Astellas Pharma US INC | $236.34 | 2021-2024 | Veozah, Myrbetriq |
| Sanofi-Aventis U.S. LLC | $231.55 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $218.32 | 2021-2024 | Jardiance, Tradjenta, Synjardy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $209.05 | 2021-2025 | Xifaxan |
| Janssen Pharmaceuticals, INC | $203.36 | 2021-2024 | Xarelto |
| Amgen INC. | $179.13 | 2021-2025 | Repatha, Otezla, Repatha |
| Takeda Pharmaceuticals U.S.A., INC. | $129.87 | 2021-2024 | Trintellix |
| Phathom Pharmaceuticals, INC. | $126.65 | 2024-2025 | Voquezna |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $125.17 | 2024-2025 | Korlym |
| Merck Sharp & Dohme LLC | $74.09 | 2021 | |
| Dexcom, INC. | $63.11 | 2023-2025 | Dexcom G6 Transmitter |
| Idorsia Pharmaceuticals US INC | $58.29 | 2023-2024 | Quviviq |
| Bayer Healthcare Pharmaceuticals INC. | $31.54 | 2022 | |
| Amarin Pharma, INC. | $30.67 | 2022 | |
| Aimmune Therapeutics, INC. | $30.37 | 2024-2025 | Zenpep |
| Biohaven Pharmaceutical Holding Company LTD. | $28.60 | 2022 | |
| Boston Scientific Corporation | $27.87 | 2023 | Watchman Access System |
| Mylan Specialty L.P. | $27.78 | 2022-2023 | Yupelri |
| Vivus LLC | $23.45 | 2023 | Qsymia |
| Insulet Corporation | $20.10 | 2025 | Omnipod |
| Viatris Specialty LLC | $19.34 | 2025 | Yupelri |
| Abbott Laboratories | $17.85 | 2024 | Freestyle Libre 3 |
| Almatica Pharma LLC | $17.12 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $15.10 | 2025 | Zoryve |
| Linus Health, INC. | $13.63 | 2023 | |
| Nestle Healthcare Nutrition INC. | $11.34 | 2021 | |
| Genentech USA, INC. | $3.82 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kendra Proctor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.